Research and Development Progress on Plant-made Pharmaceuticals

doi:10.13560/j.cnki.biotech.bull.1985.2017-0177

Abstract

Abstract:

Compared with the traditional production methods,the use of transgenic plants as bioreactor for the production of pharmaceutical proteins and vaccines is considered to be low-cost,safer and more convenient. At present,a number of plant-made pharmaceutical proteins have been approved for commercialization,while a group of plant-made vaccines have entered clinical trials. Research and development of plant-made vaccines and pharmaceutical proteins are reviewed,main problems and challenges are discussed,and the future technology development is prospected.

Key words: plant bioreactor, vaccine, pharmaceutical protein, expression system

LIU Rong-rong. Research and Development Progress on Plant-made Pharmaceuticals[J]. Biotechnology Bulletin, 2017, 33(9): 17-22.

References

[1] 刘培磊, 李宁, 连庆, 等. 利用植物生物反应器生产药用蛋白的研究进展[J] . 生物技术进展, 2013（5）：309-316.
[2] Ma J, Drake P, Christou P. The production of recombinant pharmaceutical proteins in plants[J] . Nat Rev Genet, 2003（4）：794-805.
[3] Streatfield S, Kushnir N, Yusibov V, Plant-produced candidate cou-ntermeasures against emerging and reemerging infections and biote-rror agents[J] . Plant Biotechnology Journal, 2015, （13）：1136-1159.
[4] Chan H, Daniell H. Plant-made oral vaccines against human infectious diseases—Are we there yet?[J] Plant Biotechnology Journal, 2015, （13）：1056-1070.
[5] Shahid N, Daniell H. Plant-based oral vaccines against zoonotic and non-zoonotic diseases[J] . Plant Biotechnology Jounal, 2016, 14：2079-2099.
[6] Peyret H, Lomonossoff G. When plant virology met Agrobacterium：the rise of the deconstructed clones[J] . Plant Biotechnology Journal, 2015（13）：1121-1135.
[7] Fuqua J, Hamorsky K, Khalsa G, et al. Bulk production of the antiviral lectin griffithsin[J] . Plant Biotechnology Journal, 2015, （13）：1160-1168.
[8] Velasquez L, Shira S, Berta A, et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine[J] . Vaccine, 2011, （29）：5221-5231.
[9] Ruiz V, Mozgovoj M, Santos M, et al. Plant-produced viral bovine vaccines：what happened during the last 10 years?[J] Plant Biotechnology Journal, 2015, （13）：1071-1077.
[10] Takaiwa F, Wakasa Y, Takagi H, et al. Rice seed for delivery of vaccines to gut mucosal immune tissues[J] . Plant Biotechnology Journal, 2015, （13）：1041-1055.
[11] Sack M, Rademacher T, Spiegel H, et al. From gene to harvest：insights into upstream process development for the GMP production of a monoclonal antibody in transgenic tobacco plants[J] . Plant Biotechnology Journal, 2015, （13）：1094-1105.
[12] Ma J, Drossard J, Lewis D. Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants[J] . Plant Biotechnology Journal, 2015（13）：1106-1120.
[13] 叶玲玲, 仇炜祎, 田德桥, 等. 埃博拉病毒疫苗和药物的研发进展及启示[J] . 生物技术通讯, 2015, 26（1）：5-9.
[14] Arntzen C. Plant-made pharmaceuticals：from “Edible Vaccines” to Ebola therapeutics[J] . Plant Biotechnology Journal, 2015, （13）：1013-1016.
[15] Kwon K, Daniell H. Low-cost oral delivery of protein drugs bioencapsulated in plant cells[J] . Plant Biotechnology Journal, 2015, （13）：1017-1022.
[16] Su J, Sherman A, Doerfler P, et al. Oral delivery of acid alpha glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Promp mice[J] . Plant Biotechnology Journal, 2015, （13）：1023-1032.
[17] 陈金梅, 姜路壹, 洪治. 植物生物反应器制药的现状及展望[J] . 生物技术通报, 2015, 31（10）：1-7.